2022
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Goh G, Seet J, Chee C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Teh J, Lwin A, Soon Y, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8597-8605. PMID: 36070113, DOI: 10.1245/s10434-022-11998-z.Peer-Reviewed Original ResearchConceptsGastric cancer peritoneal metastasisIP-PTXConversion surgeryIntraperitoneal paclitaxelMedian OSSystemic chemotherapyPeritoneal metastasisSC groupConversion to negative cytologyResultsThe median OSProgression-free survivalPhase II studyMethodsForty-four patientsIntravenous oxaliplatinMedian PFSOral capecitabineSystemic capecitabineExtraperitoneal metastasesNegative cytologyPeritoneal diseaseOverall survivalPerformance statusPrimary endpointSecondary endpointsIP cohortReal-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.
Ang C, Low Q, Ho C, Walsh R, Asokumaran Y, Choo J, Chan G, Ho J, Ang Y, Tan L, Yong W, Sundar R, Chee C. Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. Journal Of Clinical Oncology 2022, 40: 3584-3584. DOI: 10.1200/jco.2022.40.16_suppl.3584.Peer-Reviewed Original ResearchMetastatic colorectal cancerTAS-102Median PFSBiweekly dosesDiscontinued treatment due to toxicityColorectal cancerDose of TAS-102Treated with TAS-102Treatment due to toxicityMetastatic colorectal cancer patientsGrade 3 neutropeniaThird-line treatmentInitiation of treatmentRetrospective observational studyBiweekly regimenDose delaysFebrile neutropeniaHigher neutropeniaStandard regimenDose reductionBevacizumabGrade 3Adverse eventsDisease progressionNeutropenia
2021
Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.
Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Cheng Ean C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Shabbir A, Yong W, So J. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2021, 39: 165-165. DOI: 10.1200/jco.2021.39.3_suppl.165.Peer-Reviewed Original ResearchIP paclitaxelSystemic chemotherapyPeritoneal metastasisConversion surgeryGastric cancerMedian OSSC groupProspective phase 2 trialIP groupProgression-free survivalPhase II studyBaseline performance statusWound-related complicationsStandard-of-careGCPM patientsIntraperitoneal paclitaxelIV oxaliplatinMedian PFSSystemic capecitabineExtraperitoneal metastasesNegative cytologyOverall survivalPerformance statusPrimary endpointSecondary endpoints